ArticleUnited European gastroenterology journal2023

Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort.

Beatriz Gros et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.